Comments
The year ends with a mixed bag of fortunes for the pharmaceutical and medical technology industry. While the stage is set for Government to exercise price control on stents (devices used to remove blockages in heart procedures), the Delhi High Court has quashed an earlier ban by the Government on 344 combination drugs. Both situations could go into another round of litigation or long drawn out discussions that delay the outcome for the patient. Late December will also see Sandoz discontinue its Turbhe site (Maharashtra), as part of a global strategy to optimize manufacturing.
As for 2017, the med-tech industry will have to cope with life under a price control regime, even as the pharma world is optimistic of an improvement in its growth trajectory.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.